Advertisement
About Rib-X Pharmaceuticals, Inc.
Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drugdiscovery and development company focused on the structure-based design of newclasses of antibiotics. The Company's underlying drug discovery enginecapitalizes on its proprietary high-resolution crystal structure of theribosome, which performs an essential role in the fundamental process ofprotein synthesis. Many known, commercially valuable antibiotics bind to theribosome, including those used to treat both community-acquired and hospital-acquired pathogens. The Company's integrated research strategy, which combinesstate of the art, proprietary computational analysis, X-ray crystallography,medicinal chemistry, microbiology and biochemistry, allows it to rapidlysynthesize new agents designed to avoid typical antibiotic resistancemechanisms. Rib-X's iterative intelligent engine has yielded severaldistinctive new antibiotic classes. The Company currently has two programs inhuman clinical trials, the radezolid (RX-1741) designer oxazolidinone programas an oral/IV agent to treat serious hospital Gram-positive infections and thedelafloxacin, (RX-3341) program, a next generation fluoroquinolone, activeagainst a broad spectrum of bacteria, including methicillin-resistantStaphylococcus aureus. Additionally, the Company has multiple drug discoveryprograms. The first of these is an exciting discovery program that is well onits way toward the identification of new chemical classes of antibioticsactive against multi-drug resistant Gram-negative bacteria in the hospital.The second of these programs is focused on design and development of an IV andorally active macrolide for treatment of infections in the nursing home andhospital setting, including those caused by MRSA and enterococci. Radezolidand the multiple discovery programs derive from Rib-X's proprietary use of theribosome structure and computational tools.
For more information on the ribosome and the Rib-X mission, please visitthe Company website at www.rib-x.com.
SOURCE Rib-X Pharmaceuticals, Inc.
